Cargando…

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer

BACKGROUND: Immune checkpoint blockade (ICB) therapy has brought remarkable clinical benefits to patients with advanced non-small cell lung carcinoma (NSCLC). However, the prognosis remains largely variable. METHODS: The profiles of immune-related genes for patients with NSCLC were extracted from TC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Shuai, Jiang, Dongjie, Zhang, Feng, Li, Kun, Jiao, Kun, Hu, Jingyun, Song, Haihan, Ma, Qin-Yun, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924230/ https://www.ncbi.nlm.nih.gov/pubmed/36793597 http://dx.doi.org/10.3389/fonc.2023.1095313

Ejemplares similares

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
por: Guo, Dina, et al.
Publicado: (2020)

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2019)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis
por: Zhou, Quanwei, et al.
Publicado: (2020)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
por: Song, Zhuo, et al.
Publicado: (2022)

Pan-Cancer Analysis Shows Enrichment of Macrophages, Overexpression of Checkpoint Molecules, Inhibitory Cytokines, and Immune Exhaustion Signatures in EMT-High Tumors
por: Tiwari, Jayesh Kumar, et al.
Publicado: (2022)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy
por: Barrón, Feliciano, et al.
Publicado: (2020)

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme
por: Yu, Ziye, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Development of an Immune-Related Gene Signature for Prognosis in Melanoma
por: Zhang, Jia-An, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma
por: Song, Congkuan, et al.
Publicado: (2020)

An Immune-Related Gene Pairs Signature for Predicting Survival in Glioblastoma
por: Wang, Sheng, et al.
Publicado: (2021)

Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
por: Principe, Daniel R., et al.
Publicado: (2021)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2020)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer
por: Asano, Yohei, et al.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85ojhovvpa1p6ln2camma812lo